Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents.

Londregan AT, Wei L, Xiao J, Lintner NG, Petersen D, Dullea RG, McClure KF, Bolt MW, Warmus JS, Coffey SB, Limberakis C, Genovino J, Thuma BA, Hesp KD, Aspnes GE, Reidich B, Salatto CT, Chabot JR, Cate JHD, Liras S, Piotrowski DW.

J Med Chem. 2018 Jul 12;61(13):5704-5718. doi: 10.1021/acs.jmedchem.8b00650. Epub 2018 Jun 25.

PMID:
29878763
2.

Assessing the Feasibility of Neutralizing Osteopontin with Various Therapeutic Antibody Modalities.

Farrokhi V, Chabot JR, Neubert H, Yang Z.

Sci Rep. 2018 May 17;8(1):7781. doi: 10.1038/s41598-018-26187-w.

3.

Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing.

Weng Y, Ishino T, Sievers A, Talukdar S, Chabot JR, Tam A, Duan W, Kerns K, Sousa E, He T, Logan A, Lee D, Li D, Zhou Y, Bernardo B, Joyce A, Kavosi M, O'Hara DM, Clark T, Guo J, Giragossian C, Stahl M, Calle RA, Kriz R, Somers W, Lin L.

Sci Rep. 2018 Mar 9;8(1):4241. doi: 10.1038/s41598-018-22456-w.

4.

Liver-Targeted Small-Molecule Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9 Synthesis.

McClure KF, Piotrowski DW, Petersen D, Wei L, Xiao J, Londregan AT, Kamlet AS, Dechert-Schmitt AM, Raymer B, Ruggeri RB, Canterbury D, Limberakis C, Liras S, DaSilva-Jardine P, Dullea RG, Loria PM, Reidich B, Salatto CT, Eng H, Kimoto E, Atkinson K, King-Ahmad A, Scott D, Beaumont K, Chabot JR, Bolt MW, Maresca K, Dahl K, Arakawa R, Takano A, Halldin C.

Angew Chem Int Ed Engl. 2017 Dec 18;56(51):16218-16222. doi: 10.1002/anie.201708744. Epub 2017 Nov 24.

PMID:
29073340
5.

Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates.

Kim AM, Somayaji VR, Dong JQ, Rolph TP, Weng Y, Chabot JR, Gropp KE, Talukdar S, Calle RA.

Diabetes Obes Metab. 2017 Dec;19(12):1762-1772. doi: 10.1111/dom.13023. Epub 2017 Jul 21.

PMID:
28573777
6.

Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome.

Dong JQ, Gosset JR, Fahmi OA, Lin Z, Chabot JR, Terra SG, Le V, Chidsey K, Nouri P, Kim A, Buckbinder L, Kalgutkar AS.

Drug Metab Dispos. 2017 May;45(5):501-511. doi: 10.1124/dmd.116.074476. Epub 2017 Mar 2.

PMID:
28254951
7.

Physiologically relevant binding affinity quantification of monoclonal antibody PF-00547659 to mucosal addressin cell adhesion molecule for in vitro in vivo correlation.

Wang M, Kussrow AK, Ocana MF, Chabot JR, Lepsy CS, Bornhop DJ, O'Hara DM.

Br J Pharmacol. 2017 Jan;174(1):70-81. doi: 10.1111/bph.13654. Epub 2016 Nov 30.

8.

A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects.

Talukdar S, Zhou Y, Li D, Rossulek M, Dong J, Somayaji V, Weng Y, Clark R, Lanba A, Owen BM, Brenner MB, Trimmer JK, Gropp KE, Chabot JR, Erion DM, Rolph TP, Goodwin B, Calle RA.

Cell Metab. 2016 Mar 8;23(3):427-40. doi: 10.1016/j.cmet.2016.02.001.

9.

Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice.

Weng Y, Chabot JR, Bernardo B, Yan Q, Zhu Y, Brenner MB, Vage C, Logan A, Calle R, Talukdar S.

PLoS One. 2015 Mar 19;10(3):e0119104. doi: 10.1371/journal.pone.0119104. eCollection 2015.

10.

Comprehensive mechanism-based antibody pharmacokinetic modeling.

Chabot JR, Dettling DE, Jasper PJ, Gomes BC.

Conf Proc IEEE Eng Med Biol Soc. 2011;2011:4318-23. doi: 10.1109/IEMBS.2011.6091072.

PMID:
22255295
11.

Two additive mechanisms impair the differentiation of 'substrate-selective' p38 inhibitors from classical p38 inhibitors in vitro.

Hendriks BS, Seidl KM, Chabot JR.

BMC Syst Biol. 2010 Mar 15;4:23. doi: 10.1186/1752-0509-4-23.

12.

Cellular imaging predictions of clinical drug-induced liver injury.

Xu JJ, Henstock PV, Dunn MC, Smith AR, Chabot JR, de Graaf D.

Toxicol Sci. 2008 Sep;105(1):97-105. doi: 10.1093/toxsci/kfn109. Epub 2008 Jun 3.

PMID:
18524759
13.

Stochastic gene expression out-of-steady-state in the cyanobacterial circadian clock.

Chabot JR, Pedraza JM, Luitel P, van Oudenaarden A.

Nature. 2007 Dec 20;450(7173):1249-52.

PMID:
18097413
14.

Analysis of mechanistic pathway models in drug discovery: p38 pathway.

Hendriks BS, Hua F, Chabot JR.

Biotechnol Prog. 2008 Jan-Feb;24(1):96-109. Epub 2007 Oct 5.

PMID:
17918858
15.

Probing polymerization forces by using actin-propelled lipid vesicles.

Upadhyaya A, Chabot JR, Andreeva A, Samadani A, van Oudenaarden A.

Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4521-6. Epub 2003 Mar 25.

16.

[10 year results of preoperative radiotherapy in treatment of rectal carcinoma].

Reed WP, Garb JL, Stark AJ, Chabot JR, Friedmann P.

Chirurg. 1996 Jun;67(6):621-4. German.

PMID:
8767090
17.

The influence of local tumor ulceration on the effectiveness of endocavitary radiation for patients with early rectal carcinoma.

Reed WP, Cataldo PA, Garb JL, Stark AJ, O'Connor CE, Chabot JR.

Cancer. 1995 Sep 15;76(6):967-71.

PMID:
8625222
18.

Long-term results and complications of preoperative radiation in the treatment of rectal cancer.

Reed WP, Garb JL, Park WC, Stark AJ, Chabot JR, Friedmann P.

Surgery. 1988 Feb;103(2):161-7.

PMID:
3340985
19.

Intestinal anastomosis after preoperative radiation therapy for carcinoma of the rectum.

Friedmann P, Garb JL, McCabe DP, Chabot JR, Park WC, Stark A, Coe NP, Page DW.

Surg Gynecol Obstet. 1987 Mar;164(3):257-60.

PMID:
3547721
20.

Survival following moderate-dose preoperative radiation therapy for carcinoma of the rectum.

Friedmann P, Garb JL, Park WC, Stark A, DeConti RC, Chabot JR, Pace OT.

Cancer. 1985 Mar 1;55(5):967-73.

PMID:
3967205
21.

Jejunal carcinoma in a child.

Cordts AE, Chabot JR.

J Pediatr Surg. 1983 Apr;18(2):180-1.

PMID:
6854502
22.

Adjuvant radiation therapy in colorectal carcinoma.

Friedmann P, Park WC, Afonya II, Chabot JR, Garb JL, Pace OT, Emery RW.

Am J Surg. 1978 Apr;135(4):512-8.

PMID:
637197

Supplemental Content

Loading ...
Support Center